louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05230095: Social Cognition Dysfunctions in Parkinson's Disease
Official title: Social Cognition Dysfunctions in Parkinson's Disease
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Keywords: Parkinson Disease
emotional recognition
Deep Brain Stimulation
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2022-02-08
Enrollment: 24
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients likely to participate in the study and verifying the eligibility criteria will be identified within the Neurology C department as part of their neurological follow-up before and after deep brain stimulation.

Healthy volunteers will be recruited among the spouses of the patients or via association like France Parkinson.

Brief summary: Parkinson's disease (PD) is usually responsible of cognitive and behavioral non-motor signs with a major impact on the quality of life. Social cognition is a complex system relying on emotion recognition (neurons mirror system (NMS)), the theory of mind (with its two parts: emotional and cognitive), but also on the social and cultural environment and the personal history. The first step in this model is represented by the NMS, which seems to be altered in PD patients for both positive and negative emotions as shown in our preliminary study. The investigator purpose is to investigate the role of the treatment (levodopa and deep brain stimulation) on the functioning of the NMS


Eligibility criteria: Inclusion Criteria:

For all participants:

* Man or woman
* Participant not objecting to participation in the study
* Age ≥ 30 and ≤ 70 years old

Specific inclusion criteria for patients:

* Patients with Parkinson's disease with motor fluctuations and dyskinesias receiving deep-brain stimulation
* Patients able to understand the issues of the study

Exclusion Criteria:

For all participants:

* Person deprived of liberty by judicial or administrative decision
* Person subject to a legal protection measure (tutorship, curatorship)
* Person concurrently participating in another research project who may interfere with the results or conclusions of this study

Specific exclusion criteria for healthy volunteers

* Person presenting or having presented a neurological or psychiatric pathology
* Person with a serious medical condition
* Person who has exceeded the annual amount of compensation authorized for participation in research protocols

Primary outcomes:
measure: Emotional resonance task score
timeFrame: 12 months following the inclusion
Secondary outcomes:
measure: Correlations between the emotional resonance task score and patients' quality of life self-questionnaire score (PDQ39)
timeFrame: 12 months following the inclusion
Other outcomes:
Locations:
city: Bron
country: France
facility: Neurology C department, P. Wertheimer Hospital
Study officials:
References:
Clinical trial NCT01976195: High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP
Official title: An Open-label, Randomized Multicenter Investigation of High-dose Dexamethasone Combining Thalidomide Versus High-dose Dexamethasone Mono-therapy for Management of Newly-diagnosed Immune Thrombocytopenia
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Immune Thrombocytopenia
Keywords: Thalidomide
Dexamethasone
ITP
Lead sponsor: Shandong University
Sponsor class: OTHER
Collaborators: name: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
name: Anhui Medical University
name: The First Affiliated Hospital of Dalian Medical University
name: Shenzhen Second People's Hospital
First posted: 2013-11-05
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The project was undertaking by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone for the treatment of adults with primary immune thrombocytopenia (ITP), compared to conventional high-dose dexamethasone mono-therapy.

Detailed description: The investigators are undertaking a multicenter, randomized controlled trial of 200 primary ITP adult patients from 5 medical centers in China. One part of the participants are randomly selected to receive Thalidomide (given at a dose of 150mg for 15 consecutive days), combining with dexamethasone (given intravenously at a dose of 40 mg per day for 4 days, the others are selected to receive high-dose of dexamethasone treatment (given intravenously at a dose of 40 mg daily for 4 days).

Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of thalidomide combining with high-dose dexamethasone therapy compared to high-dose dexamethasone for the treatment of adults with ITP.

Eligibility criteria: Inclusion Criteria:

* •newly diagnosed ITP patients need of treatment(s) to minimize the risk of clinically significant bleeding primary ITP confirmed by excluding other supervened causes of thrombocytopenia

Exclusion Criteria:

* •pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment hepatitis C virus, HIV, HBsAg seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

Primary outcomes:
measure: Evaluation of platelet response
timeFrame: Newly diagnosed ITP in 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Qilu hospital, Shandong University
state: Shandong
Study officials:
References:
Clinical trial NCT02191995: Yoga in the Treatment of Eating Disorders: a Randomized Trial
Official title: Yoga in the Treatment of Eating Disorders: a Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anorexia Nervosa
Bulimia Nervosa
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2014-07-16
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Yoga facilitates the treatment of eating disorders by decreasing symptom severity over time.


Eligibility criteria: Inclusion Criteria:

* admitted to the Anna Westin House treatment facility of the Emily Program in MN during timeframe study is being run

Exclusion Criteria:

* declines participation in study

Primary outcomes:
measure: Participants' level of mood and anxiety
timeFrame: Week 4
Secondary outcomes:
measure: Level of eating disorder symptoms
timeFrame: Week 4
measure: Participants' ability to tolerance distress
timeFrame: Week 4
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: The Emily Program
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Dianne Neumark-Sztainer, PhD MPH RD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Carol Peterson, PhD LP
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Scott Crow, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: The Emily Program
name: Lisa Diers, RD LD RYT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00776295: Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer
Official title: Phase II Trial of Autologous Peripheral Blood Hematopoietic Cell Transplantation (PBHCT) Followed by Dendritic Cell p53 Vaccination and Adoptive T Cell Transfer in Patients With Limited Stage Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Small Cell Lung Cancer
Keywords: Small Cell Lung Cancer
SCLC
Limited Stage Small Cell Lung Cancer
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute
Sponsor class: OTHER
First posted: 2008-10-21
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether p53 vaccination followed by high dose chemotherapy and autologous HCT and T cell therapy significantly induces immune responses resulting in 1-year survival greater that the current 70%.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed SCLC who presented with Limited Stage (LS) at diagnosis.
* Measurable disease at the time of initial therapy
* Appropriate treatment for LS-SCLC including radiotherapy and chemotherapy.
* Responsive disease to standard chemoradiation therapy as defined by RECIST
* Patients with CR after chemoradiation therapy are strongly recommended to be treated with prophylactic cranial irradiation
* CBC with an absolute neutrophil count (ANC) \>/= 1,000/uL, hemoglobin \>/= 8.0 g/DL and platelet count \>/= 75,000/uL.
* Normal prothrombin time (PT) and partial thromboplastin time (aPTT), unless on monitored anticoagulation therapy for medical conditions not excluded in the trial.
* Liver enzymes: total bilirubin less than or equal to 2mg/dL; AST and ALT less than 1.5X the upper limit of normal.
* Creatinine clearance of \>/= 60 mL/min
* Pulmonary: DLCO greater than 50%
* Cardiac: left ventricular ejection fraction greater than 45%

Exclusion Criteria:

* Patient with stable (SD) or progressive disease (PD) after 4 cycles of standard cisplatin and etoposide and concurrent chest irradiation
* Pregnant or lactating woman
* HIV infection confirmed by NAT
* Common variable immunodeficiency
* Active CNS malignancy
* Active bacterial, fungal or viral infection
* Unfavorable psychosocial evaluation or history of poor compliance to prescribed medical care
* Prior history of autologous or allogeneic hematopoietic cell transplantation
* Presence of protocol specific comorbid conditions

Primary outcomes:
measure: Number of Subjects Meeting 1-year Overall Survival
timeFrame: up to one year
Secondary outcomes:
measure: 3 Year Progression-free Survival
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Tampa
country: United States
facility: HLeeMoffitt
state: Florida
Study officials:
affiliation: H. Lee Moffitt Cancer Center
name: Mohamed Kharfan-Dabaja, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06310395: Analysis of the Acute Mesenteric Ischemia in a Single Institution Over 10 Years
Official title: Analysis of the Acute Mesenteric Ischemia Management in a Single Institution Over 10 Years
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Acute Mesenteric Ischemia
Keywords: Mesenteric ischemia
Acute Mesenteric ischemia
Abdominal pain
Elderly
Complications
Mortality
Lead sponsor: Hospital del Mar
Sponsor class: OTHER
First posted: 2024-03-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients admited in Hospital del Mar from 2014 to 2023 with a diagnostic of AMI

Brief summary: Acute mesenteric ischemia (AMI) is a notorious disease with a high mortality, the diagnostic and management is truly multidisciplinary, but it is not the reality in many Hospitals.

The aim of this study is to analyse the results of the patients admitted with an AMI in Hospital de Mar.

Detailed description: Acute mesenteric ischemia (AMI) is a notorious disease with a high mortality from 50 to 80%. Even though AMI is a relatively rare condition (1:1,000) the incidence rises exponentially with increasing age, in patients older than 75 years, the incidence of AMI has been reported higher than that of acute appendicitis. AMI patients benefit from early assessment in a surgical unit with capabilities to definitive management. The diagnosis and management of AMI are truly multidisciplinary, requiring high index of suspicion and awareness from emergency department physicians, preferably computed tomography angiography with precise interpretation.

The aim of this study is to analyse the results of the patients admitted with an AMI in Hospital de Mar from January 2014 to December 2023.

Eligibility criteria: Inclusion Criteria:

* Acute Mesenteric Ischemia

Exclusion Criteria:

* Chronic Mesenteric Ischemia
* Ischemic Colitis
* Bowel obstruction strangulation
* Inflamatory bowel necrosis

Primary outcomes:
measure: Mortality
timeFrame: 2014-2023
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06314295: Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods
Official title: Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Coronary Artery Disease
Lead sponsor: Beijing Hospital
Sponsor class: OTHER_GOV
First posted: 2024-03-18
Enrollment: 1500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with suspected coronary artery disease who plan to undergo coronary angiography

Brief summary: The incidence rate and mortality of coronary artery disease are increasing year by year. Exploring non-invasive, accurate, and widely applicable methods to screen and diagnosis is of great significance. New ultrasound techniques, such as non-invasive myocardial work, have been proven to be superior to traditional ultrasound techniques in screening and diagnosis. However, diagnostic analysis based on ultrasound video images is time-consuming and subjective. The progress of artificial intelligence technology in fully automated quantitative evaluation of video images provides the possibility for computer-aided design screening and diagnosis. At present, the application of artificial intelligence in computer-aided design is a cutting-edge issue in the field of cardiovascular disease research. The application of artificial intelligence technology in the construction of computer-aided diagnostic models based on ultrasound video images is still in its early stages.

Detailed description: 1) Clarify the value of new cardiac ultrasound techniques indicators in coronary artery disease diagnosis; 2) To achieve classification and detection of cardiac ultrasound sections; Implementing automatic segmentation and recognition of the left ventricular cavity, left ventricular myocardium, and left atrial wall contours through the CLAS model; Using the another model to achieve heart motion tracking and synthesizing velocity vector maps of the heart flow field. 3) Verify and optimize the coronary artery disease fully automated artificial intelligence diagnostic model mentioned above.

Eligibility criteria: Inclusion Criteria:

Patients with suspected coronary artery disease who plan to undergo coronary angiography

Exclusion Criteria:

Patients with ①Aortic valve stenosis, aortic valve replacement surgery, hypertrophic cardiomyopathy; ②Severe heart valve disease, arrhythmia, cardiomyopathy, congenital heart disease; ③The quality of ultrasound images is poor.

Primary outcomes:
measure: Different coronary angiography results
timeFrame: Coronary angiography examination within 2-3 days after admission
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00438295: Temperature Control During Dialysis Treatment
Official title: Effect of Temperature Control During Dialysis Treatment With Glucose in Dialysis Water in Patients With Chronic Renal Failure
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Renal Failure, Chronic
Keywords: glucose in dialysis water, dialysis treatment, temperature
Lead sponsor: Regional Hospital Holstebro
Sponsor class: OTHER
First posted: 2007-02-22
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose is to measure the effect of glucose in the dialysis water on blood pressure, pulse rate, and plasma glucose with and without body temperature control

Detailed description: To clarify the influence of temperature in dialysis water on blood pressure and vasoactive hormones

Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years,
2. both men and women,
3. chronic renal failure and dialysis treatment for at least three months

Exclusion Criteria:

1. Heart failure,
2. Lung insufficiency,
3. Chronic liver disease,
4. Diabetes mellitus,
5. Malignant disease,
6. Nephrotic syndrome,
7. Lack of compliance,
8. Unwillingness til participate

Primary outcomes:
measure: Effect of temperature control on blood pressure, pulse rate and blod glucose during dialysis treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Holstebro
country: Denmark
facility: Holstebro Hospital
Study officials:
affiliation: Regional Hospital Holstebro
name: Erling B Pedersen, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT03455595: CONECCT (Colorectal Neoplasia Endoscopic Classification To Chose the Endoscopic Treatment)
Official title: CONECCT Score so as to Improve the Diagnosis and the Treatment of Colorectal Neoplasia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Digestive System Disease
Lead sponsor: Hôpital Edouard Herriot
Sponsor class: OTHER
First posted: 2018-03-06
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population with colorectal polyps

Brief summary: Prospective study so as to evaluate CONECCT score to determine both histological tissue and therapeutic choice


Eligibility criteria: Inclusion Criteria:

* N/A

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Evaluation of the CONECCT endoscopic score so as to improve colon therapeutic treatment polyps
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Lyon
country: France
facility: Edouard Herriot Hospital
state: Rhône Alpes
Study officials:
References:
Clinical trial NCT00365495: Influence of Physical Training on Mitochondrial Function in Type 2 Diabetic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Type 2 Diabetes
Keywords: Type 2 diabetes
physical training
mitochondrial function
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2006-08-17
Enrollment: 30
Sex: MALE
Minimum age (years): 40
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Physical activity as treatment for patients with type 2 diabetes (T2D). Treatment of T2D is often done by medication, changing the diet and increased physical activity. It is well established that physical training has a positive effect on the pathology of T2D such as increased insulin sensitivity and reduced fasting plasma glucose (7) and blood lipids (15). It is also well known that in healthy subjects endurance training increases mitochondrial density, lipid oxidation during submaximal exercise, and results in a number of qualitative changes in the control of OXPHOS (24). However, the effect of physical training on the mitochondrial function in skeletal muscle of patients with T2D has not been investigated.

The purpose of this project is to investigate the effect of physical training on the mitochondrial respiratory function in muscles of patients with T2D. Skeletal muscle biopsies will be taken before and after 10 weeks of physical training in patients with T2D and matched control subjects. Mitochondria will be isolated from the muscle biopsies, and respiratory function, free radical production and UCP3 will be determined. Furthermore, measures of maximal oxygen consumption (VO2max), heart rate and capillary lactate concentrations and carbohydrate and lipid oxidation will be determined partly to verify an increased aerobic capacity and partly to investigate the changes in these factors in T2D patients.


Eligibility criteria: Inclusion Criteria:

* Male,
* BMI above 26,
* Age between 40 and 65,
* Living a sedentary lifestyle

Exclusion Criteria:

* Women
* BMI under 26
* Age under 40 and over 65
* Trained subjects Control subjects: relatives to type 2 diabetic patients, T2D trial subjects

Primary outcomes:
measure: Mitochondrial respiratory measurements. The investigations are carried out by two rounds - one before Christmas and one after.
Secondary outcomes:
measure: VO2max
measure: Lipid oxidation
measure: muscle fiber type composition
measure: muscle oxidative enzymes
measure: mitochondrial-specific proteins (UCP3)
measure: mitochondrial production of free oxygen radicals
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: University of Southern Denmark and Odense University Hospital
Study officials:
affiliation: University of Southern Denmark
name: Martin Mogensen, PhD student
role: PRINCIPAL_INVESTIGATOR
References: